Researchers Find Missing Link in Autoimmune Disorder (SAVI)

Newly described protein drives immune response, offers potential target for treatment

Human cells prepare to release infection-fighting molecules called cytokines (magenta). WashU Medicine researchers identified a protein crucial to this process and how it is involved in a rare autoimmune disease. (Credit: David Kast)

Autoimmune diseases, which are estimated to affect more than 15 million people in the U.S., occur when the body responds to immune-system false alarms, and infection-fighting first responders are sent out to attack threats that aren’t there. Scientists have long understood how the false alarms get triggered, but the second step of dispatching the immune response has been a mystery. Now, scientists at Washington University School of Medicine in St. Louis and the Perelman School of Medicine at the University of Pennsylvania, together with colleagues, have identified a key component to launching immune activity – and overactivity. The researchers identified a protein in cells that spurs the release of infection-fighting molecules. The protein, whose role in the immune system had not previously been suspected, provides a potential target for therapies that could prevent overreactive immune responses that are at the root of several debilitating illnesses. Their paper appeared online in Cell on February 12, 2025. The article is titled “ArfGAP2 Promotes STING Proton Channel Activity, Cytokine Transit, and Autoinflammation.”

Full Story

How Solving a Hepatitis B Paradox Opens the Door to New Therapies

Model of a human hepatitis B disease virus capsid. (Credit: theasis)

Hepatitis B virus (HBV) affects 300 million people worldwide and is a major driver of liver diseases. But while decades of research have led to vaccines, antivirals, and a better understanding of the virus, how this pathogen establishes persistent infection in cells at the molecular level remains poorly understood. Now, a collaboration among The Rockefeller University, Memorial Sloan Kettering Cancer Center (MSK), and Weill Cornell Medicine has uncovered a key mechanism that allows HBV to infect liver cells. Their research, published February 20, 2025 in Cell, suggests that the virus hijacks host chromatin structures to activate its own genes. The findings solve a long-standing mystery about the basic biology of the virus while also pointing to an anticancer drug candidate that, at relatively low doses, may disrupt HBV’s ability to establish long-lasting infection in liver cells. The Cell article is titled “A Nucleosome Switch Primes Hepatitis B Virus Infection.”

Full Story